Literature DB >> 32304955

Engineering probiotics for therapeutic applications: recent examples and translational outlook.

Nikhil Aggarwal1, Amy M Ehrenworth Breedon2, Christina M Davis2, In Young Hwang1, Matthew Wook Chang3.   

Abstract

Engineered probiotics are the next generation of live biotherapeutics that have been genetically modified to target specific diseases. With the advancements in synthetic biology, the engineering of probiotics has become increasingly sophisticated which has led to the development of therapies for treating cancer, infection, metabolic disorders and inflammation, as well as for diagnosing and preventing them. Herein, we review some of the recent examples of probiotics which have been engineered to target such diseases. Although there are numerous examples of engineered probiotics showing efficacy in animal models, there are no approved products on the market with very few in clinical trials. Therefore, we also discuss a set of features that may be incorporated into engineered probiotics to aid in clinical translation and ultimately, realizing the potential of these biotherapeutics.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Year:  2020        PMID: 32304955     DOI: 10.1016/j.copbio.2020.02.016

Source DB:  PubMed          Journal:  Curr Opin Biotechnol        ISSN: 0958-1669            Impact factor:   9.740


  14 in total

1.  Construction of a sustainable 3-hydroxybutyrate-producing probiotic Escherichia coli for treatment of colitis.

Authors:  Xu Yan; Xin-Yi Liu; Dian Zhang; Yu-Dian Zhang; Zi-Hua Li; Xu Liu; Fuqing Wu; Guo-Qiang Chen
Journal:  Cell Mol Immunol       Date:  2021-09-03       Impact factor: 22.096

Review 2.  Function and therapeutic value of astrocytes in neurological diseases.

Authors:  Hong-Gyun Lee; Michael A Wheeler; Francisco J Quintana
Journal:  Nat Rev Drug Discov       Date:  2022-02-16       Impact factor: 112.288

Review 3.  Engineered probiotics.

Authors:  Junheng Ma; Yuhong Lyu; Xin Liu; Xu Jia; Fangyun Cui; Xiaoheng Wu; Shanshan Deng; Changwu Yue
Journal:  Microb Cell Fact       Date:  2022-04-27       Impact factor: 6.352

Review 4.  Intestinal Inflammation as a Dysbiosis of Energy Procurement: New Insights into an Old Topic.

Authors:  J Scott Lee; Ruth X Wang; Erica E Alexeev; Sean P Colgan
Journal:  Gut Microbes       Date:  2021 Jan-Dec

Review 5.  Probiotic Effects against Virus Infections: New Weapons for an Old War.

Authors:  Aroa Lopez-Santamarina; Alexandre Lamas; Alicia Del Carmen Mondragón; Alejandra Cardelle-Cobas; Patricia Regal; José Antonio Rodriguez-Avila; José Manuel Miranda; Carlos Manuel Franco; Alberto Cepeda
Journal:  Foods       Date:  2021-01-09

6.  Development of a Genome-Scale Metabolic Model and Phenome Analysis of the Probiotic Escherichia coli Strain Nissle 1917.

Authors:  Dohyeon Kim; Youngshin Kim; Sung Ho Yoon
Journal:  Int J Mol Sci       Date:  2021-02-20       Impact factor: 5.923

7.  An engineered Mycoplasma pneumoniae to fight Staphylococcus aureus.

Authors:  Dominick Matteau; Sébastien Rodrigue
Journal:  Mol Syst Biol       Date:  2021-10       Impact factor: 11.429

8.  Bioactive peptides produced by engineered probiotics and other food-grade bacteria: A review.

Authors:  Haydee Eliza Romero-Luna; Adrián Hernández-Mendoza; Aarón Fernando González-Córdova; Audry Peredo-Lovillo
Journal:  Food Chem X       Date:  2021-12-22

9.  Open source anaerobic and temperature-controlled in vitro model enabling real-time release studies with live bacteria.

Authors:  Juliane Fjelrad Christfort; Chrysillis Judy Magaard Polhaus; Pi Westi Bondegaard; Tien-Jen Chang; En Te Hwu; Line Hagner Nielsen; Kinga Zór; Anja Boisen
Journal:  HardwareX       Date:  2022-02-05

10.  Self-tunable engineered yeast probiotics for the treatment of inflammatory bowel disease.

Authors:  Benjamin M Scott; Cristina Gutiérrez-Vázquez; Liliana M Sanmarco; Jessica A da Silva Pereira; Zhaorong Li; Agustín Plasencia; Patrick Hewson; Laura M Cox; Madelynn O'Brien; Steven K Chen; Pedro M Moraes-Vieira; Belinda S W Chang; Sergio G Peisajovich; Francisco J Quintana
Journal:  Nat Med       Date:  2021-06-28       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.